Neurocrine Biosciences (NBIX) director reports option exercises and stock sales

Rhea-AI Filing Summary

A director of Neurocrine Biosciences, Inc. reported stock transactions in mid-December 2025. On December 15, 2025, the director exercised 8,276 stock options at $92.35 per share and 1,724 options at $84.95 per share, converting them into common stock. That same day, the director sold 5,000 shares of common stock at a weighted average price of $152.2287 per share, followed by an additional sale of 1,190 shares on December 16, 2025 at a weighted average price of $155.0911 per share. After these trades, the director beneficially owned 6,239 shares of Neurocrine common stock. The filing notes that the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, and that company policy restricts changes to such plans after adoption.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norwalk Leslie V

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M		8,276	A	$92.35	10,705	D
Common Stock	12/15/2025		M		1,724	A	$84.95	12,429	D
Common Stock	12/15/2025		S(1)		5,000	D	$152.2287(2)	7,429	D
Common Stock	12/16/2025		S(1)		1,190	D	$155.0911(3)	6,239	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$92.35	12/15/2025		M			8,276	(4)	05/19/2031	Common Stock	8,276	$0	557	D
Non-Qualified Stock Option	$84.95	12/15/2025		M			1,724	(5)	05/18/2032	Common Stock	1,724	$0	0	D

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.09 to $155.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. The option was granted on May 19, 2021 and vested in 12 equal monthly installments beginning June 19, 2021.

5. The option was granted on May 18, 2022 and vested in 12 equal monthly installments beginning June 18, 2022.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Neurocrine Biosciences (NBIX) report in this Form 4?

The filing shows a director of Neurocrine Biosciences (NBIX) exercised stock options and sold shares in December 2025, with the sales made under a Rule 10b5-1 trading plan.

How many Neurocrine Biosciences (NBIX) options were exercised in this filing?

On December 15, 2025, the director exercised 8,276 options at $92.35 per share and 1,724 options at $84.95 per share, converting them into Neurocrine common stock.

How many Neurocrine Biosciences (NBIX) shares were sold and at what prices?

The director sold 5,000 shares on December 15, 2025 at a weighted average of $152.2287 and 1,190 shares on December 16, 2025 at a weighted average of $155.0911 per share.

How many Neurocrine Biosciences (NBIX) shares does the insider hold after these transactions?

Following the reported option exercises and sales, the director beneficially owned 6,239 shares of Neurocrine Biosciences common stock.

Were the Neurocrine Biosciences (NBIX) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected by a broker under a Rule 10b5-1 trading plan adopted on September 12, 2025, and notes that issuer policy restricts modifying such plans after adoption.

What are the key details of the stock options reported for Neurocrine Biosciences (NBIX)?

The reported non-qualified stock options had exercise prices of $92.35 and $84.95, were granted in May 2021 and May 2022, and vested in 12 equal monthly installments starting in June 2021 and June 2022, respectively.